Table 1. Patient demographics and... | Rockefeller University Press

Table 1.

Patient demographics and baseline characteristics

Parameter	Thalidomide (n = 3)			Placebo (n = 5)
Parameter	T1	T2	T3	P1	P2	P3	P4	P5
Age, years	6	25	1	1	28	28	8	1
Sex	Male	Male	Male	Male	Male	Male	Male	Male
Genotype	CYBB	CYBB	CYBB	CYBB	CYBB	CYBB	NCF2	CYBB
Weight, kg	14.6	67.1	9.6	10.7	46.5	51.2	23.7	9.3
PUCAI at screening	45	40	35	40	35	35	30	40
PUCAI at 0 wk	15	45	25	50	35	40	35	25
PGA at screening	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate	Mild	Mild
PGA at 0 wk	Mild	Moderate	Mild	Moderate	Moderate	Moderate	Mild	Mild
Infection at initiation of trial	–	–	–	–	–	–	–	Thymic abscess
Concomitant drugs at 0 wk	TMP-SMX	Meropenem	Cefditoren pivoxil	TMP-SMX	TMP-SMX	TMP-SMX	TMP-SMX	Cefmetazole
Concomitant drugs at 0 wk	Itraconazole	Itraconazole	Itraconazole	Fluconazole	Itraconazole	Itraconazole	Itraconazole	Micafungin

Parameter	Thalidomide (n = 3)			Placebo (n = 5)
Parameter	T1	T2	T3	P1	P2	P3	P4	P5
Age, years	6	25	1	1	28	28	8	1
Sex	Male	Male	Male	Male	Male	Male	Male	Male
Genotype	CYBB	CYBB	CYBB	CYBB	CYBB	CYBB	NCF2	CYBB
Weight, kg	14.6	67.1	9.6	10.7	46.5	51.2	23.7	9.3
PUCAI at screening	45	40	35	40	35	35	30	40
PUCAI at 0 wk	15	45	25	50	35	40	35	25
PGA at screening	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate	Mild	Mild
PGA at 0 wk	Mild	Moderate	Mild	Moderate	Moderate	Moderate	Mild	Mild
Infection at initiation of trial	–	–	–	–	–	–	–	Thymic abscess
Concomitant drugs at 0 wk	TMP-SMX	Meropenem	Cefditoren pivoxil	TMP-SMX	TMP-SMX	TMP-SMX	TMP-SMX	Cefmetazole
Concomitant drugs at 0 wk	Itraconazole	Itraconazole	Itraconazole	Fluconazole	Itraconazole	Itraconazole	Itraconazole	Micafungin

PUCAI, Pediatric Ulcerative Colitis Activity Index; PGA, Physician Global Assessment; TMP-SMX, trimethoprim/sulfamethoxazole.